S-1: BioAffinity Launches Public Offering Amid Nasdaq Delisting Threat

BioAffinity Technologies, Inc. announced a public offering of common stock and warrants to raise capital, following a reverse stock split and ongoing Nasdaq compliance challenges.

Summary

• BioAffinity Technologies, Inc. is offering up to 729,927 shares of Common Stock, up to 1,094,891 Common Stock Purchase Warrants, and up to 729,927 Pre-Funded Warrants.
• The offering also includes Placement Agent Warrants to purchase up to 21,898 shares of Common Stock, with a total of up to 1,846,716 shares underlying all warrants.
• The assumed public offering price is $5.48 per share of Common Stock and accompanying September 2025 Warrant, which was the closing price on Nasdaq on September 17, 2025, adjusted for a 1-for-30 reverse stock split.
• September 2025 Warrants have an exercise price of $5.48 per share and expire five years after the Initial Exercise Date, exercisable upon shareholder approval or immediately if 'Pricing Conditions' are met.
• Pre-Funded Warrants are offered to purchasers whose beneficial ownership would exceed 4.99% (or 9.99%) and have an exercise price of $0.007 per share, immediately exercisable.
• The company estimates net proceeds of approximately $3.4 million from this offering, which will be used for working capital and general corporate purposes.
• A 1-for-30 reverse stock split became effective on September 18, 2025, with trading on a split-adjusted basis commencing September 19, 2025.
• As of June 30, 2025, the company reported an actual cash and cash equivalents balance of $802,835, with a pro forma as adjusted balance of $9,262,526 after the offering.
• Actual total stockholders' equity (deficit) was $(2,136,108) as of June 30, 2025, improving to a pro forma as adjusted $4,525,801 after the offering.
• The company faces potential delisting from Nasdaq due to non-compliance with the minimum $1.00 bid price requirement and the $2.5 million stockholders' equity requirement, with an extension granted until October 2, 2025, to regain compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant financial challenges, including a stockholders' equity deficit, substantial dilution for new investors, and an explicit 'going concern' warning from auditors. The ongoing Nasdaq delisting threat further underscores the precarious financial and operational state, despite the capital raise attempt.

Positives

• The offering aims to raise approximately $3.4 million in net proceeds, providing capital for working capital and general corporate purposes.
• The company's pro forma as adjusted cash and cash equivalents are projected to increase significantly to $9,262,526, and total stockholders' equity to $4,525,801, improving its financial position.
• Recent board appointments of Roberto Rios, CPA and John J. Oppenheimer, M.D. strengthen corporate governance.
• The company continues to advance development of its flow cytometry+AI platform for companion diagnostic tests for COPD and asthma, and research into novel cancer therapeutic approaches.

Negatives

• The company has a limited operating history, making it difficult to evaluate its business and future prospects.
• There is substantial doubt about the company's ability to continue as a going concern, as noted in the auditor's report.
• The company has a historical net tangible book value deficit of $(4.52) per share as of June 30, 2025.
• New investors will experience immediate and substantial dilution of $4.72 per share in net tangible book value.
• The company faces a significant risk of delisting from the Nasdaq Capital Market due to non-compliance with listing standards, including minimum bid price and stockholders' equity requirements.
• The offering is a 'best efforts' offering with no minimum amount of securities required to be sold, meaning the company may not raise sufficient capital for its business plans.
• The September 2025 Warrants may not be exercisable until shareholder approval is obtained, and if approval is not secured, they will have no value.
• There is no public market for the September 2025 Warrants and Pre-Funded Warrants, limiting their liquidity.

Risks

• Reliance on obtaining additional sources of capital and financing to fund operations and continue as a going concern.
• Difficulty in evaluating the business and future prospects due to a limited operating history.
• Inability to precisely estimate when significant profit will be generated from Precision Pathology Laboratory Services (PPLS).
• Limited experience operating a laboratory.
• Delays or difficulties in patient enrollment for clinical trials could delay or prevent regulatory approvals.
• Clinical trials are expensive, time-consuming, and may not be successful.
• Diagnostic tests may not perform as expected, negatively impacting operating results, reputation, and business.
• Difficulties may arise in developing, introducing, or marketing enhanced or new diagnostic tests.
• Even with marketing approval, commercialization of diagnostic tests or therapeutic products may not be successful.
• Dependence on PPLS to offer and perform CyPath Lung.
• Challenges in convincing physicians of the benefits of diagnostic tests or therapeutic products, potentially delaying market acceptance.
• Substantial competition in the biotechnology and pharmaceutical industries.
• Inability to retain key executives and attract/retain qualified personnel.
• Difficulty managing growth due to lack of operating experience.
• Dependence on third parties for manufacturing, marketing, trial design, and monitoring.
• Exposure to product liability and pre-clinical/clinical liability risks.
• Failure to comply with privacy and security regulations could result in liability or reputational harm.
• Inability to obtain adequate reimbursement for diagnostic tests may impact revenues.
• Potential misconduct or improper activities by employees, consultants, partners, and vendors.
• Failure to comply with healthcare laws and regulations could result in substantial penalties.
• The market for proposed tests and products is competitive and rapidly changing.
• Healthcare cost containment initiatives and managed care growth may limit returns.
• Disruption of internal information technology systems will adversely affect the business.
• Declining general economic or business conditions may negatively impact the business.
• Global climate change and related regulations could negatively affect the business.
• PPLS operations depend on relationships of certain pathologists with existing customers.
• PPLS may be unable to maintain equipment or generate revenue when equipment is not operational.
• Damage or inoperability of the sole laboratory facility, loss of accreditation, or requirement to vacate could jeopardize PPLS's ability to sell products or provide diagnostic assays.
• Disruption in commercial courier delivery services for sputum samples could harm PPLS's business.
• Security breaches, data loss, and other disruptions could compromise sensitive information of PPLS's business.
• Liability for damages if PPLS uses hazardous chemicals in a manner that causes injury.
• Inability to successfully scale PPLS operations to support demand.
• Substantial time and resources dedicated to complex billing processes for PPLS to be paid.
• Delays of third-party billing and collection providers and in-house billing function to transmit claims to payors could adversely affect PPLS.
• Failure to comply with obligations imposed by intellectual property licenses.
• Need to obtain licenses of third-party technology that may not be available or on reasonable terms.
• Competitive position depends on intellectual property protection; diagnostic tests and therapeutic products could be subject to infringement claims.
• Potential involvement in lawsuits to protect or enforce intellectual property.
• Harm to business and competitive position if trade secrets are unprotected.
• Changes in patent law could impair ability to protect tests and product candidates.
• Patent protection could be reduced or eliminated for non-compliance with governmental requirements.
• Patent terms may be inadequate to protect diagnostic tests or therapeutic product candidates.
• Issued patents could be found invalid or unenforceable.
• Business may be harmed if patent term extension is not obtained.
• Limited geographical protection with respect to certain patents.
• Inability to build name recognition if trademarks and trade names are not adequately protected.
• Failure to comply with laws pertaining to LDTs or in vitro devices (IVDs) could adversely affect the business.
• Third-party licensors of future therapeutic products may be unable to obtain regulatory approval.
• Failure to obtain regulatory approval in foreign jurisdictions would prevent product candidates from being marketed there.
• May never obtain approval or commercialize products outside of the U.S.
• Uncertain impact of changes to healthcare policy and future healthcare reform legislation.
• Failure to meet Nasdaq listing requirements could result in delisting.
• No expectation of paying dividends in the foreseeable future.
• Common Stock market price may never exceed the exercise price of outstanding warrants.
• Holders of warrants have no rights as stockholders until warrants are exercised.
• Provisions of outstanding warrants could limit a warrant holder's ability to choose the judicial forum for disputes.
• Financial and operational projections are subject to inherent risks.
• Stock price has been, and may continue to be, volatile.
• Common Stock has often been thinly traded.
• Investment may involve tax implications.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited.
• Board can designate classes of Preferred Stock without stockholder approval.
• Provisions in corporate charter documents and Delaware law could make an acquisition more difficult.
• Provisions in Charter and A&R Bylaws may discourage stockholders from bringing lawsuits against directors and officers.
• Management collectively owns a substantial percentage of Common Stock.
• Unfavorable or no analyst research could cause stock price and trading volume to decline.
• Inability to report and file financial results accurately and timely could harm the business.
• This is a best efforts offering with no minimum, potentially leading to insufficient capital for business plans.
• Future sales and issuances of securities could result in additional dilution and cause share price to fall.
• Risk of securities class action litigation.

Future Outlook

The company expects to use the net proceeds from this offering for working capital and general corporate purposes. It continues to advance development of its diagnostic platform for COPD and asthma and research into novel cancer therapeutic approaches, with findings expected to be presented at conferences and published in peer-reviewed journals. The company intends to seek strategic partners for its therapeutic discoveries. However, the ability to obtain additional funding for operations, regulatory approvals, and successful commercialization remains uncertain.

Management Comments

• Maria Zannes, Chief Executive Officer, is listed as the signatory for the company on the filing.

Industry Context

BioAffinity Technologies operates in the highly competitive biotechnology and pharmaceutical industries, specializing in noninvasive diagnostics for early-stage lung cancer and other lung diseases, leveraging flow cytometry and AI. The company's focus on early detection and companion diagnostics aligns with broader industry trends towards precision medicine and personalized healthcare. However, it faces intense competition from established players and emerging companies, and its success is contingent on market acceptance, regulatory approvals, and effective commercialization in a rapidly changing market.

Comparison to Industry Standards

• The company's financial position, particularly its historical net tangible book value deficit and ongoing need for capital, indicates it is an early-stage or distressed company compared to established industry benchmarks.
• The Nasdaq delisting threat for failing to meet minimum bid price and stockholders' equity requirements suggests performance below typical public company standards and peer companies.
• The 'best efforts' nature of the offering, with no minimum raise, is common for smaller, higher-risk companies that may not attract firm commitments from underwriters, contrasting with more robust offerings by larger, more stable industry players.
• The 1-for-30 reverse stock split is a measure often taken by companies to meet exchange listing requirements and improve stock price perception, a common practice among companies facing delisting.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience significant dilution from the offering and potential further dilution from warrant exercises. Existing shareholders face a substantial decrease in net tangible book value per share. The ongoing Nasdaq delisting threat poses a risk to liquidity and share value.
• Investors in the offering: Will incur immediate and substantial dilution. Their investment is highly speculative due to the company's financial condition and 'going concern' warning. They will have rights to purchase common stock and warrants, with some warrants requiring shareholder approval for exercise.
• Employees: The company's ability to continue as a going concern and its financial stability directly impact job security and potential equity-based compensation value.
• Customers (PPLS): Continued operations and service quality depend on the company's financial health and ability to scale operations.
• Creditors: The 'going concern' warning and need for capital raise indicate increased risk for existing and potential creditors.

Next Steps

• The company will seek shareholder approval for the exercise of September 2025 Warrants, if required.
• The company must demonstrate compliance with Nasdaq's Minimum Bid Price Requirement and Continued Listing Equity Requirement by October 2, 2025, to avoid delisting.
• The company intends to use the net proceeds from the offering for working capital and general corporate purposes.
• Continue advancing development of its flow cytometry+AI platform for companion diagnostic tests for COPD and asthma.
• Continue research and development for novel cancer therapeutic approaches, including topical treatment for squamous cell skin cancer.
• Present findings at conferences and publish research in peer-reviewed journals in the near future.
• Seek strategic partners to develop therapeutic discoveries.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a significant stockholders' equity deficit, an explicit 'going concern' warning from its auditors, and an imminent threat of delisting from Nasdaq. While the current offering aims to raise capital, it is a 'best efforts' offering with no guarantee of sufficient funds, and new investors will experience immediate and substantial dilution. The combination of these factors indicates a highly speculative and risky investment with a high probability of further capital erosion and potential business failure. Seasoned investors would likely avoid or exit this position due to the overwhelming negative indicators and lack of clear path to sustainable profitability.

Keywords

BioAffinity Technologies, Public Offering, Common Stock, Warrants, Pre-Funded Warrants, SEC Filing, S-1 Registration, Nasdaq Delisting, Reverse Stock Split, Capital Raise, Diagnostics, Lung Cancer, Flow Cytometry, AI, Biotechnology, Healthcare, Financial Health, Corporate Governance, Risk Factors